Eli Lilly and Company and POINT Biopharma Global, Inc. announced a definitive agreement for Lilly to acquire POINT, a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. Radioligand therapy can enable the precise targeting of cancer by linking a radioisotope to a targeting molecule that delivers radiation directly…
Lilly, a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world has announced a definitive agreement to acquire Disarm Therapeutics, a privately-held biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration. Disarm has discovered novel, potent SARM1 inhibitors and…
Eli Lilly and Company announced the successful completion of its acquisition of Dermira, Inc. Lilly completed the acquisition of Dermira through the merger of Bald Eagle Acquisition Corporation with and into Dermira, with Dermira surviving the merger as a wholly-owned subsidiary of Lilly. As of the expiration of the tender offer, 40,926,025 shares of Dermira…